Strategy

Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.

The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it?

How will US healthcare reform affect drug pricing, revenue, and compliance?

After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth?

As head of GSK's North American pharma, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning as the first female Big Pharma CEO.

Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.

A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?

Pricing, promotion, and the unfinished story of healthcare reform dominated the news last year.

In a digital world, vast quantities of data at hand are a powerful asset. Managing that information is key to seizing competitive advantage.

Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?

Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?

The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts.

Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.

As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.

Sales compensation practices are due for an overhaul in 2010.

In a disruptive era of change, old-fashioned intuition still counts.

Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer?

GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries.

Designing and deploying company copay offset programs without devaluing the brand.

Competitive simulations can help pharma adjust to market changes by identifying effective action steps.

Transparency can be a double-edged sword - especially if you are a doctor receiving money to speak on behalf of a drug company. Sure the pay day is nice, but does the public outing open you up to scrutiny?

Alexandra Kibble of Thomson Reuters identifies the products and therapy areas to watch next year.

With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions.

A new study of industry tax professionals conducted by PricewaterhouseCoopers predicts higher taxes for Big Pharma in the wake of the global economic downturn. What can your company do to remain competitive and discover new incentives?

The business philosophy and tools that revolutionized Toyota could save the ailing drug industry a lot more than just time and money. But is pharma really capable of getting lean?

Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network.

Developing countries will receive the scarce vaccine for free, as GSK remains confident it will fulfill contractual vaccine obligations around the world.

Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.

A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.